Objective: We sought to determine if chronic rhinosinusitis (CRS) patients with nasal polyps (CRSwNP) differentially perceived CRS symptom burden compared to patients without nasal polyps (CRSsNP) and to what extent CRS symptom severity was associated with quality of life (QOL) and patient-reported symptom control in the 2 groups.
Methods: A total of 600 patients (266 CRSwNP and 334 CRSsNP) presenting with CRS were recruited. CRS symptom burden was assessed with the 22-item Sinonasal Outcome Test (SNOT-22). SNOT-22 nasal, sleep, ear/facial discomfort, and emotional subdomain scores were calculated. General health-related QOL was assessed with the visual analog scale of the 5-dimensional EuroQol questionnaire (EQ-5D VAS). Patients rated their CRS symptom control on a 5-point scale.
Results: SNOT-22 scores did not differ between CRSwNP (mean: 35.6) and CRSsNP (mean: 36.3). There were no differences in nasal, sleep, and emotional subdomains of the SNOT-22. CRSsNP had higher ( = .003) ear/facial subdomain scores than CRSwNP, while CRSwNP reported greater hyposmia ( < .001). EQ-5D VAS was significantly lower ( = .011) in CRSsNP (mean: 68.9) compared to CRSwNP (mean: 73.2). However, CRSwNP patients reported significantly less symptom control, compared to CRSsNP, in association with nasal and emotional symptoms.
Conclusion: CRSwNP and CRSsNP have differences in symptom profile, effect on health-related QOL, and patient-perceived symptom control. CRSsNP experience significantly greater burden of ear/facial discomfort, while CRSwNP report greater hyposmia. Although CRSsNP reports lower general health-related QOL overall, CRSwNP patients had lower levels of CRS symptom control for every incremental increase in symptom burden suggesting greater sensitivity/intolerance to CRS symptoms.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/1945892420927244 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Scrotal wall necrosis after hipec using mitomycin-c: Case report and review of the literature.
Int J Surg Case Rep
January 2025
Urology Department, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Italy.
Introduction: Hyperthermic intraperitoneal chemotherapy (HIPEC) is a current treatment option for peritoneal carcinosis (PC) after cytoreductive surgery (CRS). Genital skin alterations are rare complications reported variously after HIPEC using Mitomycin-C.
Presentation Of Case: A 42-year-old man with a diagnosis of stage IV colorectal cancer underwent CRS and HIPEC using mitomycin-C.
Efficacy of endoscopic sinus surgery in patients under six years old.
Int J Pediatr Otorhinolaryngol
December 2024
Division of Otolaryngology-Head & Neck Surgery, Children's National Medical Center, Washington, D.C, USA. Electronic address:
Objectives: To examine safety and efficacy of very young patients under the age of six who underwent endoscopic sinus surgery (ESS) at our institution for the indications of either complicated acute rhinosinusitis (ARS) or chronic rhinosinusitis (CRS).
Methods: Retrospective cohort review of patients under six years old who underwent ESS for sinonasal pathology between 2016 and 2023 at a freestanding pediatric hospital. Age, sex, weight, diagnosis, laterality of disease, medications, types and number of surgical interventions, usage of image guidance, and outcomes were obtained from the medical record.
Treatment Decision-Making Among Chinese Americans With Chronic Rhinosinusitis.
Laryngoscope
January 2025
Suzanne Dworak-Peck School of Social Work, University of Southern California, Los Angeles, California, U.S.A.
Objective: There has been limited research on the influence of race and ethnicity on treatment decision-making for chronic rhinosinusitis (CRS). This prospective study aims to investigate potential factors linked to treatment modality choice among patients with medically refractory CRS, distinguishing between Chinese American and non-Chinese American patients.
Methods: CRS patients with persistent symptoms despite prior medical treatment were prospectively enrolled.
Severe Immune Effector Cell-Associated Neurotoxicity Syndrome in a Patient With Multiple Myeloma Treated With Elranatamab.
Cureus
December 2024
Department of Hematology, Japanese Red Cross Medical Center, Tokyo, JPN.
Elranatamab is an effective drug for triple-class-exposed relapsed/refractory multiple myeloma (TCE-RRMM). In the pivotal study, only grade 1 or 2 immune effector cell-associated neurotoxicity syndrome (ICANS) were reported, and the risk factors for immune effector cell-associated neurotoxicity syndrome have not yet been clearly elucidated. This case report documents the first case of grade 4 ICANS in a patient treated with elranatamab, presenting alongside grade 1 cytokine release syndrome (CRS).
View Article and Find Full Text PDFCross‑Cultural Validation of the Chronic Rhinosinusitis Patient-Reported Outcomes (CRS-PRO) Questionnaire in Portuguese.
Cureus
November 2024
Rhinology and Anterior Skull Base Surgery, University of Western Ontario, Ontario, CAN.
Introduction Chronic rhinosinusitis (CRS) presents with different clinical patterns with variable responses to treatment. Clear criteria for specifying disease severity and assessing symptom control are lacking in the current literature. We aimed to perform a cross-cultural adaptation of the chronic rhinosinusitis patient-reported outcomes (CRS-PRO), creating a Portuguese version to use as a routine questionnaire in the evaluation of patients with CRS.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!